{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:02:42Z","timestamp":1748664162500,"version":"3.41.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02543-x","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:04:03Z","timestamp":1748574243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling the TEC-associated landscape in hepatocellular carcinoma: a comprehensive study based on multi-omics analyses"],"prefix":"10.1007","volume":"16","author":[{"given":"Jianwei","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dekun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"3","key":"2543_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10360","key":"2543_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet (London, England). 2022;400(10360):1345\u201362.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2543_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, Qin W, Fan J, Wang C, Gao Q. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024;42(2):180\u201397.","journal-title":"Cancer Cell"},{"issue":"1","key":"2543_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","volume":"80","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, Dai J, Yu K, Zhang Y, Baheti T, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol. 2024;80(1):82\u201398.","journal-title":"J Hepatol"},{"key":"2543_CR5","first-page":"1","volume":"1","author":"Y Lu","year":"2024","unstructured":"Lu Y, Liu Y, Zuo X, Li G, Wang J, Liu J, Wang X, Wang S, Zhang W, Zhang K, et al. CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma. J Hepatol. 2024;1:1.","journal-title":"J Hepatol"},{"issue":"1","key":"2543_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-021-01205-8","volume":"20","author":"Z Yu","year":"2022","unstructured":"Yu Z, Guo J, Liu Y, Wang M, Liu Z, Gao Y, Huang L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnol. 2022;20(1):9.","journal-title":"J Nanobiotechnol"},{"issue":"20","key":"2543_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"2","key":"2543_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig. 2018;128(2):580\u20138.","journal-title":"J Clin Investig"},{"issue":"27","key":"2543_CR9","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I\/II Study. J Clin Oncol. 2021;39(27):2991\u20133001.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2543_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"1","key":"2543_CR11","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/s41467-019-13056-x","volume":"10","author":"D Kobak","year":"2019","unstructured":"Kobak D, Berens P. The art of using t-SNE for single-cell transcriptomics. Nat Commun. 2019;10(1):5416.","journal-title":"Nat Commun"},{"issue":"2","key":"2543_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"12","key":"2543_CR13","first-page":"1572","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England). 2010;26(12):1572\u20133.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"2543_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"7269","key":"2543_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108\u201312.","journal-title":"Nature"},{"issue":"4","key":"2543_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"2543_CR17","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"11","key":"2543_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/nm.4405","volume":"23","author":"JY Goh","year":"2017","unstructured":"Goh JY, Feng M, Wang W, Oguz G, Yatim S, Lee PL, Bao Y, Lim TH, Wang P, Tam WL, et al. Chromosome 1q213 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat Med. 2017;23(11):1319\u201330.","journal-title":"Nat Med"},{"key":"2543_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1479-5876-11-182","volume":"11","author":"V L\u00f3pez","year":"2013","unstructured":"L\u00f3pez V, Gonz\u00e1lez-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, Vidal A, Bellmunt J, Heredero O, S\u00e1nchez-Carbayo M. Identification of prefoldin amplification (1q233-q241) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med. 2013;11:182.","journal-title":"J Transl Med"},{"key":"2543_CR20","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.2147\/IJGM.S360177","volume":"15","author":"R Zhou","year":"2022","unstructured":"Zhou R, Zhu X, Peng Y, Zhong L, Peng L, Yang B, Meng Y, Chen X, Lu Y. Clinical Impact of 11q13.3 amplification on immune cell infiltration and prognosis in breast cancer. Int J Gen Med. 2022;15:4037\u201352.","journal-title":"Int J Gen Med"},{"issue":"9","key":"2543_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/onc.2012.132","volume":"32","author":"D Yin","year":"2013","unstructured":"Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene. 2013;32(9):1155\u201363.","journal-title":"Oncogene"},{"issue":"6","key":"2543_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","volume":"68","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065\u201375.","journal-title":"Gut"},{"issue":"2","key":"2543_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/HEP.0000000000000553","volume":"79","author":"B Li","year":"2024","unstructured":"Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, Peng J, Li H, Zhang L, Su K, et al. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology (Baltimore, MD). 2024;79(2):289\u2013306.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7391","key":"2543_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Leh\u00e1r J, Kryukov GV, Sonkin D, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137.","journal-title":"Nature"},{"issue":"5","key":"2543_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"4","key":"2543_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):41.","journal-title":"Genome Biol"},{"issue":"1","key":"2543_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H, Wang L, Lu T, Zhang Y, Sun Z, et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816.","journal-title":"Nat Commun"},{"issue":"2","key":"2543_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccr.2013.06.004","volume":"24","author":"M Masiero","year":"2013","unstructured":"Masiero M, Sim\u00f5es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013;24(2):229\u201341.","journal-title":"Cancer Cell"},{"issue":"6","key":"2543_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315.","journal-title":"Nat Med"},{"issue":"8","key":"2543_CR30","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1158\/0008-5472.CAN-22-1844","volume":"83","author":"JH Fang","year":"2023","unstructured":"Fang JH, Chen JY, Zheng JL, Zeng HX, Chen JG, Wu CH, Cai JL, Wang ZY, Zhuang SM. Fructose metabolism in tumor endothelial cells promotes angiogenesis by activating AMPK signaling and mitochondrial respiration. Can Res. 2023;83(8):1249\u201363.","journal-title":"Can Res"},{"key":"2543_CR31","doi-asserted-by":"publisher","first-page":"14361","DOI":"10.1038\/ncomms14361","volume":"8","author":"E Dejana","year":"2017","unstructured":"Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. Nat Commun. 2017;8:14361.","journal-title":"Nat Commun"},{"issue":"1","key":"2543_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17\u201335.","journal-title":"Immunity"},{"issue":"5","key":"2543_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","volume":"272","author":"AA Schnitzbauer","year":"2020","unstructured":"Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272(5):855\u201362.","journal-title":"Ann Surg"},{"issue":"5","key":"2543_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/annonc\/mdw054","volume":"27","author":"D Koeberle","year":"2016","unstructured":"Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77\/08 and SASL 29). Ann Oncol. 2016;27(5):856\u201361.","journal-title":"Ann Oncol"},{"issue":"3","key":"2543_CR35","first-page":"315","volume":"28","author":"KA Bouchagier","year":"2014","unstructured":"Bouchagier KA, Assimakopoulos SF, Karavias DD, Maroulis I, Tzelepi V, Kalofonos H, Karavias DD, Kardamakis D, Scopa CD, Tsamandas AC. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients\u2019 survival. In vivo (Athens, Greece). 2014;28(3):315\u201326.","journal-title":"In vivo (Athens, Greece)"},{"issue":"6","key":"2543_CR36","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.cmet.2020.04.022","volume":"31","author":"CH Ly","year":"2020","unstructured":"Ly CH, Lynch GS, Ryall JG. A metabolic roadmap for somatic stem cell fate. Cell Metab. 2020;31(6):1052\u201367.","journal-title":"Cell Metab"},{"issue":"3","key":"2543_CR37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability\u2013an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220\u20138.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02543-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02543-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:04:05Z","timestamp":1748574245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02543-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2543"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02543-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"951"}}